Data omitted from Soto Becerra et al; the one study showing worse outcomes with ivermectin

Missing data in Soto Becerra et al; the one study showing worse outcomes with ivermectin.

The NIH COVID-19 Treatment Guidelines provide the following recommendation on the use of ivermectin:

“There are insufficient data for the COVID-19 Treatment Guidelines Panel (the Panel) to recommend either for or against the use of ivermectin for the treatment of COVID-19…”

There are 11 clinical studies of ivermectin that are cited as the basis for this recommendation. One of those studies showed worse outcomes for patients receiving treatment with ivermectin: Soto Becera et al released onMedrxiv.

After Soto Becerra et al was released, an administrator at Instituto de Evaluación de Tecnologías en Salud e Investigación, EsSalud (IETSI) the organization that employed the authors of that article wrote a memo entitled “Memorando №1843 IETSI-ESSALUD 2020”. In that memorandum, the administrator provided a table (page 4) showing the results of the study. Those results were not included in Soto Becera et al. The results in this table showed a significant improvement in survival without ICU admission in patients who received ivermectin. The table itself is in English. The caption to the table is in Spanish. Translated, the caption to the table is...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee